Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nandrolone Phenpropionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | SHBG | P04278 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nandrolone Phenpropionate SCHEMBL29396630 | 1.00 | MAPT (1.00) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| Nandrolone Phenpropionate SCHEMBL15285479 | 1.00 | MAPT (1.00) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| Nandrolone Phenpropionate SCHEMBL29290732 | 0.97 | MAPT (0.93) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| Nandrolone Phenpropionate SCHEMBL6151232 | 0.96 | MAPT (0.92) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| Nandrolone Phenpropionate SCHEMBL1767545 | 0.93 | MAPT (0.86) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| Nandrolone Phenpropionate SCHEMBL28167686 | 0.91 | MAPT (0.82) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| SCHEMBL21067996 | 0.90 | MAPT (0.84) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| Nandrolone Phenpropionate SCHEMBL3675534 | 0.89 | MAPT (0.79) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| SCHEMBL23752494 | 0.88 | MAPT (0.78) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| SCHEMBL17419472 | 0.88 | MAPT (0.78) | MAPTLMNAALDH1A1HIF1AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 61467 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3985024-B1 | ANTI-ACTIVIN-A ANTIBODY AND CHEMOTHERAPY COMBINATION FOR THE TREATMENT OF OVARIAN CANCER | ATARA BIOTHERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | claimed |
| EP-3894839-B1 | SYSTEM SUITABILITY METHOD FOR USE WITH PROTEIN CONCENTRATION DETERMINATION BY SLOPE | AMGEN INC (US) | 2026-01-28 | — | — | EP | claimed |
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2025-12-30 | — | — | US | claimed |
| EP-4036225-B1 | METHOD FOR INDUCING DIFFERENTIATION INTO DOPAMINE NEURONAL PRECURSOR CELLS FROM STEM CELLS | S BIOMEDICS (KR) | 2025-12-24 | — | — | EP | claimed |
| EP-3765857-B1 | SEQUENTIAL DIGESTION OF POLYPEPTIDES FOR MASS SPECTROMETRIC ANALYSIS | AMGEN INC (US) | 2025-12-10 | — | — | EP | claimed |
| EP-3315606-B1 | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODY PERMEATING BLOOD-BRAIN BARRIER | JAPAN CHEM RES (JP) | 2025-11-26 | — | — | EP | claimed |
| EP-4079314-B1 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-10-29 | — | — | EP | claimed |
| EP-3828199-B1 | ALK7: ACTRIIB HETEROMULTIMERS AND USES THEREOF | ACCELERON PHARMA INC (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4070803-B1 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3749682-B1 | TREATING HETEROTOPIC OSSIFICATION | ACCELERON PHARMA INC (US) | 2025-09-24 | — | — | EP | claimed |
| US-4997815-A | Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin | CHILDREN'S HOSPITAL MEDICAL CENTER OF NORTHERN CALIFORNIA (US) | 1991-03-05 | — | — | US | claimed |
| WO-1991000095-A1 | COMPOSITIONS USEFUL AS CONTRACEPTIVES IN MALES | COHEN MICHAEL (NL) | 1991-01-10 | — | — | WO | claimed |
| CN-1048327-A | Contraceptive composition for male | COHEN MICHAEL (NL) | 1991-01-09 | — | — | CN | claimed |
| US-4935363-A | Sterol regulatory elements | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-06-19 | — | — | US | claimed |
| EP-0368992-A1 | ACTIONS OF HORMONES. | BIOTECH AUSTRALIA PTY LTD (AU) | 1990-05-23 | — | — | EP | claimed |
| EP-0367590-A2 | Augmenting fetal hemoglobin by treatment with activin and/or inhibin | Perrine, Susan P. (US) | 1990-05-09 | — | — | EP | claimed |
| EP-0353246-A1 | STEROL REGULATORY ELEMENTS. | UNIV TEXAS (US) | 1990-02-07 | — | — | EP | claimed |
| WO-1989011862-A1 | ACTIONS OF HORMONES | BIOTECHNOLOGY AUSTRALIA PTY. LTD. (AU) | 1989-12-14 | — | — | WO | claimed |
| EP-0307248-A2 | Method for increasing the expression of polypeptides in recombinant cell culture | GENENTECH, INC. (US) | 1989-03-15 | — | — | EP | claimed |
| WO-1988007579-A1 | STEROL REGULATORY ELEMENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1988-10-06 | — | — | WO | claimed |